FCA Corp TX reduced its holdings in CVS Health Corp (NYSE:CVS) by 1.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,736 shares of the pharmacy operator’s stock after selling 221 shares during the quarter. FCA Corp TX’s holdings in CVS Health were worth $1,371,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of CVS. 1 North Wealth Services LLC acquired a new position in shares of CVS Health during the 3rd quarter valued at $29,000. Centaurus Financial Inc. increased its position in shares of CVS Health by 570.8% during the 1st quarter. Centaurus Financial Inc. now owns 1,630 shares of the pharmacy operator’s stock valued at $30,000 after purchasing an additional 1,387 shares during the period. Manchester Financial Inc. acquired a new position in shares of CVS Health during the 2nd quarter valued at $31,000. Hudock Capital Group LLC increased its position in shares of CVS Health by 54.0% during the 2nd quarter. Hudock Capital Group LLC now owns 576 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 202 shares during the period. Finally, Executive Wealth Management LLC increased its position in shares of CVS Health by 62.4% during the 2nd quarter. Executive Wealth Management LLC now owns 565 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 217 shares during the period. Hedge funds and other institutional investors own 75.92% of the company’s stock.
CVS has been the topic of several research analyst reports. TheStreet upgraded CVS Health from a “c+” rating to a “b-” rating in a research report on Monday, September 9th. Barclays lifted their price target on CVS Health from $75.00 to $79.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Mizuho lifted their price target on CVS Health from $71.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, November 8th. ValuEngine upgraded CVS Health from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Cowen set a $76.00 price target on CVS Health and gave the company a “buy” rating in a research report on Monday, October 21st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $77.59.
CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.77 by $0.07. The business had revenue of $64.81 billion for the quarter, compared to analysts’ expectations of $62.99 billion. CVS Health had a return on equity of 15.45% and a net margin of 1.83%. The company’s quarterly revenue was up 36.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.73 EPS. On average, research analysts expect that CVS Health Corp will post 7.01 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Monday, November 4th. Stockholders of record on Thursday, October 24th were given a $0.50 dividend. The ex-dividend date was Wednesday, October 23rd. This represents a $2.00 annualized dividend and a dividend yield of 2.75%. CVS Health’s dividend payout ratio (DPR) is presently 28.25%.
In other news, CFO Eva C. Boratto sold 8,130 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $65.00, for a total value of $528,450.00. Following the completion of the sale, the chief financial officer now owns 55,273 shares of the company’s stock, valued at $3,592,745. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joshua Matthew Flum sold 17,703 shares of the firm’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $63.00, for a total value of $1,115,289.00. Following the completion of the sale, the executive vice president now directly owns 36,163 shares of the company’s stock, valued at approximately $2,278,269. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,437 shares of company stock valued at $3,248,811. 0.53% of the stock is currently owned by insiders.
CVS Health Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Featured Article: Economic Reports
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.